Document is current
Any future updates will be listed below
-
Authors
Lee, Ji-Hyun
Lee, Seung Hoon
Jeon, Chanhyeok
Han, Jinil
Kim, Sang-Hyon
Youn, Jeehee
Park, Ye-Soo
Kim, Tae-Jong
Kim, Jong-Seo
Jo, Sungsin https://orcid.org/0000-0003-3034-5029
Kim, Tae-Hwan https://orcid.org/0000-0002-3542-2276
Son, Chang-Nam
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (2021R1F1A1060970)
National Research Foundation of Korea (2019R1A2C2004214)
National Research Foundation of Korea (2021R1A6A1A03038899)
National Research Foundation of Korea (2020R1A2C1102386)
Korea Healthy Industry Development Institute (HI23C0661)
Daegu-Gyeongbuk Medical Innovation Foundation (B-A-H-21-02)
- License Information
-
More Information
Article History
Received: 18 August 2023
Revised: 9 January 2024
Accepted: 5 February 2024
First Online: 29 February 2024
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University Hanyang University Hospital (2014–05-002) and approved by the Animals Ethics Screening Committee of Hanyang University (2021-0229A).
: Informed consent was obtained from all individual participants included in the study.
: Ji-Hyun Lee and Jinil Han are employed by Rheumarker Bio Inc. and Gencurix Inc., respectively. Chang-Nam Son is the chief executive officer (CEO) of Rheumarker Bio Inc. Other authors declare no conflicts of interest.
